Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corporation (NASDAQ: BCPC) is a global specialty ingredient manufacturer for health and nutrition markets, and its news flow reflects this focus. Company press releases highlight the development, manufacture and marketing of specialty ingredients that improve and enhance the health and well-being of life on the planet, as well as financial and corporate updates relevant to investors and industry observers.
Visitors to this BCPC news page can review Balchem’s announcements on quarterly financial results, dividend declarations and participation in investor conferences. Recent releases have reported segment-level performance for its Human Nutrition & Health, Animal Nutrition & Health and Specialty Products segments, along with measures such as net sales, earnings from operations, adjusted EBITDA and free cash flow, as described in accompanying Form 8-K filings.
Balchem also issues news related to regulatory and trade developments that affect its markets. For example, the company joined another EU producer in welcoming European Union anti-dumping duties on choline chloride imports from China, emphasizing the importance of fair trade for the EU food and feed supply chain and for maintaining a healthy domestic choline chloride industry.
In addition, Balchem regularly announces its participation in conferences hosted by firms such as CJS Securities, Baird, H.C. Wainwright, Wells Fargo and others, where its leadership presents to the investment community. These updates provide insight into how the company communicates its strategy and segment performance to shareholders and analysts. Investors and researchers can use this news stream to follow Balchem’s financial reporting, capital allocation decisions such as dividends, and its commentary on market and regulatory conditions affecting its human nutrition, animal nutrition and specialty products businesses.
Balchem (NASDAQ: BCPC), a global specialty ingredient manufacturer focusing on health and nutrition markets, has announced its participation in the BNP Paribas Exane 13th Consumer Ingredients Conference scheduled for March 11, 2025.
The company will be represented by Ted Harris, Chairman of the Board, Chief Executive Officer, and President, along with Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations.
The announcement was made from Montvale, N.J. on February 25, 2025. This conference represents an opportunity for Balchem to engage with industry participants and potentially share insights about their operations in the specialty ingredient manufacturing sector.
Balchem (NASDAQ: BCPC) reported strong Q4 2024 financial results with record net sales of $240.0 million, up 4.9% year-over-year. The company achieved net earnings of $33.6 million, a 26.0% increase, and record adjusted EBITDA of $62.8 million, up 13.4%.
For full-year 2024, Balchem delivered record net sales of $953.7 million, a 3.4% increase, with GAAP net earnings of $128.5 million (+18.4%). The company generated strong cash flows from operations of $182.0 million and free cash flow of $147.2 million, enabling debt reduction of $119.6 million.
All three segments showed growth, with Human Nutrition & Health leading at $147.3 million (+6.8%), Animal Nutrition & Health at $58.3 million (+0.3%), and Specialty Products at $32.9 million (+6.0%). Gross margin improved to 36.0%, up 320 basis points from the prior year.
Balchem (NASDAQ: BCPC) has scheduled a conference call for Friday, February 21, 2025, at 11:00 AM Eastern Time to discuss its fourth quarter and full year 2024 financial results. The call will be hosted by Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO.
The company will release its financial results before the market opens on February 21, 2025. The press release and financial exhibits will be available on Balchem's website. Investors can join the call by dialing toll-free 1-877-407-8289 or 1-201-689-8341 locally. A replay will be available for three hours after the call until March 7, 2025, accessible by dialing 1-877-660-6853 or 1-201-612-7415 with conference ID #13751680.
Balchem (NASDAQ: BCPC), a global specialty ingredient manufacturer focusing on health and nutrition markets, has announced its participation in the upcoming CJS Securities New Ideas for the New Year Virtual Conference. The presentation is scheduled for January 14, 2025.
The company will be represented by Ted Harris (Chairman of the Board, President and Chief Executive Officer), Martin Bengtsson (Chief Financial Officer), and Allison Baurichter (Senior Director Investor Relations) at the conference.
Balchem (NASDAQ: BCPC) has declared a dividend of $0.87 per share on its common stock, payable on January 17, 2025, to stockholders of record as of December 26, 2024. This represents a 10.1% increase compared to the previous year's annual dividend. The announcement marks Balchem's sixteenth consecutive annual dividend increase, reflecting the company's consistent financial performance and the Board's confidence in their long-term strategies.
Balchem (NASDAQ: BCPC), a global specialty ingredient manufacturer focusing on health and nutrition markets, has announced its participation at Baird's 54th Annual Global Industrial Conference on November 13, 2024. The company will be represented by Ted Harris (Chairman of the Board, President and CEO), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director Investor Relations) at the presentation.
Balchem (NASDAQ: BCPC) reported strong third quarter 2024 financial results with net sales of $239.9 million, up 4.3% year-over-year. The company achieved record earnings from operations and adjusted EBITDA of $64.4 million, a 7.6% increase. Net earnings rose 16.4% to $33.8 million, with earnings per share of $1.03. The Human Nutrition and Health segment showed excellent performance with 5.4% sales growth, while Specialty Products grew 10.6%. Cash flows from operations were $51.3 million, with quarterly free cash flow of $42.2 million. The company's net debt decreased to $153.3 million with a leverage ratio of 0.6 times.
Balchem (NASDAQ: BCPC) has announced a conference call scheduled for Friday, October 25, 2024, at 11:00 AM Eastern Time to review their third quarter results. The call will be hosted by Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO.
The company will release its third quarter results prior to the market opening on the same day. The press release and accompanying financial exhibits will be available on the Balchem website before the call. Interested parties can join the conference by calling toll-free 1-877-407-8289 or 1-201-689-8341 for local dial-in.
A replay of the call will be available for three hours after its conclusion until November 8, 2024. To access the replay, dial 1-877-660-6853 (local dial-in 1-201-612-7415) and use conference ID #13749359.
Balchem (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, has announced its participation in the HC Wainwright & Co. 26th Annual Global Investment Conference on September 9, 2024. The company will be represented by key executives including Ted Harris (Chairman of the Board, President and CEO), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director Investor Relations).
This presentation at a prominent investment conference provides an opportunity for Balchem to showcase its business strategies, financial performance, and growth prospects to potential investors and industry analysts. The event could potentially impact Balchem's stock performance and investor relations.
Balchem (NASDAQ: BCPC) reported strong Q2 2024 financial results with record earnings from operations and adjusted EBITDA. Key highlights include:
- Net sales of $234.1 million, up 1.2% YoY
- Adjusted EBITDA of $62.3 million, up 5.0% YoY
- GAAP net earnings of $32.1 million, up 6.5% YoY
- GAAP EPS of $0.98, compared to $0.93 in Q2 2023
- Record adjusted EPS of $1.09, up from $1.06 in Q2 2023
- Free cash flow of $38.4 million
The Human Nutrition & Health and Specialty Products segments showed strong performance with record earnings. Balchem also launched Optifolin+®, a new choline-enriched folate ingredient. The company's net debt decreased to $202.8 million, with a leverage ratio of 0.9x.